Medication info

Acytex Tablet (Acyclovir)

Prescription medicationTabletIntravenous injectionExpired
Ingredient · strength
Acyclovir›200mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
Light blue round tablet
Packaging
For domestic use: 30 tablets/bottle, 200 tablets/bottle, for export: 100 tablets (10 tablets/PTPX10)
Approval status
Expired

MFDS item code 201903185 · Approved 2019.05.16 · Insurance code 698504100

This product's status changed to Expired on 2024.05.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of herpes zoster, treatment and prevention of herpes simplex, and treatment of chickenpox in children
Who receives it
Adults · Children
Adult administration
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg 5 times daily at 4-hour intervals for 5 days. Treatment may be extended in cases of severe initial infection. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal absorption disorders, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) It is preferable to start treatment as soon as possible after infection. In recurrent infections, treatment should preferably be started when prodromal symptoms or lesions first appear. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer 200 mg of this medicine 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg may be administered twice daily at 12-hour intervals. 2) The dose may then be reduced to 200 mg 2 ~ 3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically discontinued every 6 ~ 12 months and the patient reassessed. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg of this medicine 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal absorption disorders, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg of this medicine 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) Intravenous administration should be considered for patients with severe immunocompromise or gastrointestinal absorption disorders. 3) It is preferable to start treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Because patients with renal impairment are more likely to experience adverse reactions involving the neuropsychiatric system, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is preferable to administer 200 mg of this medicine every 12 hours. 2. Treatment of varicella-zoster virus infections 1) In patients with creatinine clearance less than 10 mL per minute, it is preferable to reduce the dose to 800 mg per administration twice daily, at approximately 12-hour intervals. 2) In patients with creatinine clearance of 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg per administration 3 times daily, at approximately 8-hour intervals.
Child administration
○ Pediatric patients 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients Age 2 years and older: Same as the adult dosage. Under 2 years: Administer 1/2 of the adult dosage. Reliable data on the prevention of herpes simplex virus infections in patients with normal immune function are not yet available. 2. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg/kg body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours after the rash appears.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of herpes zoster, treatment and prevention of herpes simplex, and treatment of chickenpox in children

  • Genital herpes
  • herpes simplex virus infection
  • herpes zoster virus infection
  • acute pain
  • chickenpox
View approved original text

This medicine is mainly used to treat and prevent primary and recurrent genital herpes, as well as other herpes simplex virus infections of the skin and mucous membranes. It is also effective in the treatment of herpes zoster virus infections and particularly helps relieve acute pain. However, its efficacy in post-herpetic neuralgia has not yet been clearly proven. It can also be used to treat chickenpox in children over 2 years of age. This medicine is widely used for various herpes virus infections.

How it is given

Adult administration

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg 5 times daily at 4-hour intervals for 5 days. Treatment may be extended in cases of severe initial infection. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal absorption disorders, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) It is preferable to start treatment as soon as possible after infection. In recurrent infections, treatment should preferably be started when prodromal symptoms or lesions first appear. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer 200 mg of this medicine 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg may be administered twice daily at 12-hour intervals. 2) The dose may then be reduced to 200 mg 2 ~ 3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically discontinued every 6 ~ 12 months and the patient reassessed. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg of this medicine 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal absorption disorders, the dose per administration may be increased to 400 mg, or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg of this medicine 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) Intravenous administration should be considered for patients with severe immunocompromise or gastrointestinal absorption disorders. 3) It is preferable to start treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Because patients with renal impairment are more likely to experience adverse reactions involving the neuropsychiatric system, use caution, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is preferable to administer 200 mg of this medicine every 12 hours. 2. Treatment of varicella-zoster virus infections 1) In patients with creatinine clearance less than 10 mL per minute, it is preferable to reduce the dose to 800 mg per administration twice daily, at approximately 12-hour intervals. 2) In patients with creatinine clearance of 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg per administration 3 times daily, at approximately 8-hour intervals.

Child administration

○ Pediatric patients 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients Age 2 years and older: Same as the adult dosage. Under 2 years: Administer 1/2 of the adult dosage. Reliable data on the prevention of herpes simplex virus infections in patients with normal immune function are not yet available. 2. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg/kg body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours after the rash appears.

Precautions

This medication should not be used in patients who have had allergic reactions to this medication, its components, or valacyclovir. Caution should be exercised when administering this medication to patients with impaired kidney function, as they can experience side effects related to the central nervous system. Patients with impaired liver function should also use this medication cautiously, as there is a risk of exacerbating liver function. In infants and children, this medication should only be used minimally when necessary, and elderly patients need to be monitored closely when using this medication. During the use of this medication, severe allergic reactions such as shock or anaphylaxis may rarely occur, so if symptoms like low blood pressure, breathing difficulties, or chest tightness appear, medication use should be immediately stopped and medical assistance should be sought. Skin reactions such as rashes, fever, blisters, or hives may occur, and if these symptoms appear, medication should be discontinued, and appropriate measures should be taken. Hair loss, severe dermatitis, or serious damage to skin and mucous membranes may rarely occur. This medication can affect mental status, causing various neurological symptoms such as altered consciousness, confusion, hallucinations, seizures, drowsiness, anxiety, etc., particularly in elderly patients or those with impaired kidney function. It may affect kidney function, potentially leading to symptoms like renal failure, hematuria, or proteinuria, so caution is required. Blood cell abnormalities can occur, resulting in conditions like anemia, leukopenia, or bleeding. Liver-related side effects including liver dysfunction, hepatitis, or jaundice have also been reported. Gastrointestinal symptoms such as gastritis, nausea, vomiting, diarrhea, and abdominal pain may occur; if these symptoms appear, medication should be discontinued, and medical consultation sought. Systemically, fever, muscle weakness, headache, and swelling may appear. Musculoskeletal symptoms such as myalgia or arthralgia have also been reported. Cardiovascular symptoms can include irregular heartbeat, blood pressure changes, and chest pain. Urinary issues such as dysuria or urinary obstruction may rarely occur. If there is no improvement in symptoms within a certain period after starting treatment with this medication, alternative treatment methods should be considered, especially if administered in the early stage of the condition for best results. Patients with weakened immune systems may require treatment in the form of intravenous injection. Adequate fluid intake during the course of administration is essential to reduce the risk of dehydration and nephrotoxicity. When treating recurrent genital herpes, continued administration after long-term use should be discussed with a physician. Caution should be taken during medication use as impaired consciousness may occur, affecting driving or machine operation, particularly for patients with decreased kidney function. Drug interactions may occur, especially with medications that affect kidney function, probenecid, cimetidine, theophylline, or mycophenolate mofetil, necessitating close attention. Women who are pregnant or of childbearing potential should only use this medication if the benefits outweigh the risks, and breastfeeding should be discontinued as the drug can be transferred to breast milk. Safety in infants and children is not established, thus it should be used cautiously only when necessary. Elderly patients should adjust dosage and administration intervals due to prolonged retention of the medication in the body caused by decreased kidney function, ensuring adequate fluid intake. In case of overdose, kidney damage can occur, so patients should be closely monitored and may require treatment such as dialysis if necessary. This medication may cause genetic anomalies or affect reproductive functions at high doses, but such effects have not been reported within recommended doses.

Side effects

  • Anaphylactic shock
  • anaphylaxis-like reaction
  • hypotension
  • respiratory distress
  • feeling of chest tightness
  • photosensitivity reaction
  • fixed drug eruption
  • rash
  • fever
  • blisters
Show 118 more
  • urticaria-like erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • concentration difficulties
  • aggressive behavior
  • depersonalization
  • anxiety
  • ataxia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • seizures
  • drowsiness
  • tremors
  • excitement
  • amnesia
  • insomnia
  • anxiety
  • soliloquy
  • altered sensation
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • dizziness
  • acute kidney failure
  • crystalluria
  • elevated BUN
  • increased serum creatinine
  • hematuria
  • proteinuria
  • urinary red blood cell casts
  • pyuria
  • leukocyte destructive vasculitis
  • lymphadenopathy
  • hemorrhage
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • loose stools
  • upper abdominal pain
  • stomach pain
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • malaise
  • generalized fatigue
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • elevated blood pressure
  • decreased blood pressure
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glycosuria
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • hair loss
  • sweating
  • hyponatremia
  • decreased serum protein
  • elevated total cholesterol
  • elevated triglycerides
  • increased serum potassium
  • decreased serum albumin
  • anxiety
  • coma
  • seizures
  • drowsiness
  • confusion
  • hallucinations
  • excitement
  • epileptic seizures
  • comatose state

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C at room temperature.

Appearance and packaging

Appearance

Light blue round tablet

Package unit

For domestic use: 30 tablets/bottle, 200 tablets/bottle, for export: 100 tablets (10 tablets/PTPX10)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.